Kidney DiseaseNCT07740083
The Effect of Patient Empowerment Learning (With AI) About Itching in Hemodylasis Patients.
A study testing Artificial Intelligence-Supported Patient Education in people with Kidney Disease and Chronc Kidney Disease Stage 5, run by Izmir Tinaztepe University at 1 site in Turkey (Türkiye).
Trial summary
This study investigates whether artificial intelligence-supported patient education can reduce itching and improve patient empowerment in individuals with chronic kidney disease undergoing hemodialysis. Read more about this study
- Who is it for?
- Ages 18 to 65 weeks
- Conditions the study is for
- Kidney Disease, Chronc Kidney Disease Stage 5, Chronic Kidney Disease
- What is being tested?
- Artificial Intelligence-Supported Patient Education
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 128 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 12 Jan 2025to 28 Aug 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 weeks
- All sexes
- No healthy volunteers
- Child
Who may be able to join
- Patients with CKD. Patients who have ithing symptom. Patients who is older than 18. Patients who takes hemodylasis treatment regularly and in order.
Who cannot join
- Patients who got dementia and alzheimers.
- Patients who is older than 65.
- Patients who doesnt want to join the study.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: The Effect of Artificial Intelligence-Supported Patient Empowerment Education on Itching in Patients With Chronic Kidney Disease Undergoing Hemodialysis
This study investigates whether artificial intelligence-supported patient education can reduce itching and improve patient empowerment in individuals with chronic kidney disease undergoing hemodialysis.
- Being tested
- Artificial Intelligence-Supported Patient Education
- Keywords
- Artificial Intelligence, CKD, Patient Empowerment
- Medical subject headings
- Kidney Diseases, Renal Insufficiency, Chronic, Patient Participation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Artificial Intelligence-Supported Patient EducationBehavioural
The intervention consisted of an artificial intelligence-supported patient education program developed for patients with chronic kidney disease undergoing hemodialysis. The education focused on pruritus management and included information about the causes of itching, factors affecting pruritus, skin care, dietary recommendations, symptom management strategies, and self-management behaviors. The educational content was provided through an AI-supported website designed to improve patient empowerment and increase patients' knowledge and participation in their own care.
| Study group | Role | What they receive |
|---|---|---|
| AI-Supported Patient Education Group | Experimental | The group who recieve the education Receives: Behavioral: Artificial Intelligence-Supported Patient Education |
| Control Group | No intervention | The group of who doesnt recieve the education |
What is being measured
The primary outcome is the main question the study is designed to answer.
5-D Itching Scale Score
Changes in 5-D Itching Scale Score
Measured: 2 weeks
Secondary outcomes (1)
Patient Empowerment Scale Score
Changes in Patient Empowerment Scale Score
Measured: 2 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted31 Jul 2026
- Study start12 Jan 2025
- Primary completion28 Apr 2026
- Study completion28 Aug 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Kidney DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- We use 5-D Itching Scale and Patient Empowerment Scale for the datas we collect from the patients. Our aim is see the effect of artificial intelligence-supported patient education in CKD patients who take hemodylasis.
- Masking
- None (open label)
- Enrolment
- 128 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Izmir Tinaztepe University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, melek arıcı, Izmir Tinaztepe University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07740083
- Sponsor's protocol ID
- MT2423257898MT465678MA45561978
- Other IDs
- MT2423257898MT465678MA45561978
- Status last verified
- Jul 2026
- First submitted
- 28 Jul 2026
- Last updated
- 31 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 31 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Effect of Artificial Intelligence-Supported Patient Empowerment Education on Itching in Patients With Chronic Kidney Disease Undergoing Hemodialysis
- ClinicalTrials.gov ID
- NCT07740083
- Acronym / sponsor ID
- MT2423257898MT465678MA45561978
- Keywords
- Artificial Intelligence, CKD, Patient Empowerment
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 128 participants (estimated)
- Lead sponsor
- Izmir Tinaztepe UniversityUniversity, hospital or other
- Study start
- 12 Jan 2025 (actual)
- Primary completion
- 28 Apr 2026 (actual)
- Study completion
- 28 Aug 2026 (estimated)
- First posted
- 31 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study investigates whether artificial intelligence-supported patient education can reduce itching and improve patient empowerment in individuals with chronic kidney disease undergoing hemodialysis.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- We use 5-D Itching Scale and Patient Empowerment Scale for the datas we collect from the patients. Our aim is see the effect of artificial intelligence-supported patient education in CKD patients who take hemodylasis.
| Arm | Type | Receives |
|---|---|---|
| AI-Supported Patient Education Group | Experimental | Behavioral: Artificial Intelligence-Supported Patient EducationThe group who recieve the education |
| Control Group | No intervention | –The group of who doesnt recieve the education |
Who may qualify
- Ages
- 18 to 65 weeks
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
Key inclusion criteria (1 listed)
- Patients with CKD. Patients who have ithing symptom. Patients who is older than 18. Patients who takes hemodylasis treatment regularly and in order.
Key exclusion criteria (3 listed)
- Patients who got dementia and alzheimers.
- Patients who is older than 65.
- Patients who doesnt want to join the study.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Artificial Intelligence-Supported Patient EducationThe intervention consisted of an artificial intelligence-supported patient education program developed for patients with chronic kidney disease undergoing hemodialysis. The education focused on pruritus management and included information about the causes of itching, factors affecting pruritus, skin care, dietary recommendations, symptom management strategies, and self-management behaviors. The educational content was provided through an AI-supported website designed to improve patient empowerment and increase patients' knowledge and participation in their own care. | Behavioural | AI-Supported Patient Education Group |
Primary outcome
5-D Itching Scale Score
Time frame: 2 weeks
Changes in 5-D Itching Scale Score
1 secondary outcome
Patient Empowerment Scale Score
Time frame: 2 weeks
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 31 Jul 2026.
- Individual participant dataSharing planned: No
Related trials for Kidney Disease
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingObservational study
Population Pharmacokinetics of Temocillin in Acute Enterobacterial Pyelonephritis in Children
Pyelonephritis
Active, not recruitingPhase 3
A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)
Carcinoma, Renal Cell
Enrolling by invitation
Online Exercise Program for Transplant Patients: A Pilot Study
Kidney Transplantation, Physical Function
Active, not recruitingPhase 2
Safety and Efficacy of Empagliflozin in Hemodialysis
End Stage Renal Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Artificial Intelligence-Supported Patient Education in people with Kidney Disease and Chronc Kidney Disease Stage 5, run by Izmir Tinaztepe University at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 31 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
5-D Itching Scale Score (time frame: 2 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 Jul 2026.